Advertisement

Prognostic factors in older patients with advanced non-small cell lung cancer in China

Abstract

Aims and background. The human life expectancy and the incidence of lung cancer have increased dramatically in recent years. As a result, there is a high demand for the management of older patients with advanced non-small cell lung cancer (NSCLC) in clinical practice. The purpose of this study is to evaluate the prognostic factors in ≥65-year-old patients with advanced NSCLC in China.
Method. This study involved a retrospective review of 78 ≥65-year-old patients with a diagnosis of NSCLC and at an advanced stage of disease, defined as stage IIIB or IV. All patients were followed up for a 3-year interval to determine the survival rates. Clinical data including gender, smoking history, comorbidities, performance status (PS), histological differentiation, disease stage, treatment and overall survival were recorded. The log-rank test was used to calculate survival rates. Multivariate Cox regression analysis was performed to determine independent prognostic factors.
Results. The 1-year, 2-year and 3-year survival rates of the 78 patients were 44.9%, 23.1% and 9.0%, respectively. In univariate analysis by the log-rank test, the 3-year survival rate was significantly associated with PS (P >0.01), disease stage (P >0.01) and chemotherapy treatment (P >0.01). The results of multivariate Cox regression analysis confirmed that PS and disease stage were independent prognostic factors.
Conclusion. The 3-year survival rate in ≥65-year-old patients with advanced NSCLC was significantly associated with PS, disease stage and chemotherapy. PS and disease stage were independent prognostic factors. Older patients with advanced NSCLC in China might benefit from chemotherapy.

Tumori 2014; 100(1): 69 - 74

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1430.15818

Authors

Qiang Su, Yu-Ping Sun, Ye-Hui Liu, Zhe Li, Hong-Yan Yang, Zhi-Gang Sun, Bang-Wei Cao, Ji-Hui Jia

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Su, Qiang [PubMed] [Google Scholar]
    Department of Medical Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
  • Sun, Yu-Ping [PubMed] [Google Scholar]
    Department of Oncology, Jinan Center Hospital Affiliated to Shandong University, Shandong University, Jinan, China
  • Liu, Ye-Hui [PubMed] [Google Scholar]
    Department of Oncology, Jinan Center Hospital Affiliated to Shandong University, Shandong University, Jinan, China
  • Li, Zhe [PubMed] [Google Scholar]
    Department of Examination Center, Jinan Center Hospital Affiliated to Shandong University, Shandong University, Jinan, China
  • Yang, Hong-Yan [PubMed] [Google Scholar]
    Department of Oncology, Jinan Center Hospital Affiliated to Shandong University, Shandong University, Jinan, China
  • Sun, Zhi-Gang [PubMed] [Google Scholar]
    Department of Thoracic Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan Center Hospital Affiliated to Shandong University, Shandong University, Jinan, China
  • Cao, Bang-Wei [PubMed] [Google Scholar]
    Department of Medical Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
  • Jia, Ji-Hui [PubMed] [Google Scholar]
    Department of Microbiology, School of Medicine, Shandong University, Jinan, China

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.